Useful outcomes from Argos AGS-004 Form 2a try in patients with HIV

Argos Therapeutics announced today that its Arcelis immunotherapy for the treatment of HIV, AGS-004, demonstrated favourable outcomes with the elemental endpoint of viral load control and a favorable sanctuary and immunogenicity profile in a final review of a Include 2a clinical trial. Text in compensation AGS-004 were presented in a poster at the 18th Symposium on Retroviruses and Exploitive Infections (CROI) in Boston.

In the mug up, AGS-004 was safe as the bank of england and poetically tolerated with no additional risks observed during structured treatment respite (STI). Argos' individualized immunotherapy resulted in an unexpectedly crave suspend in viral rebound, habits to culmination viral weight during STI and a markedly reduced viral overwhelm when compared to pre-antiretroviral psychoanalysis (ART) levels. A number of patients were masterly Buy Risnia online to endure the STI since 12 weeks, and they were abl e to initiate CD8+ T cell proliferative responses to the individualistic antigens presented in AGS-004.

The conclusive study of the Phase 2a materials reiterates our findings from the in days gone by reported interim critique that AGS-004 is poetically tolerated, immunogenic, potentially competent and safe, said Jean-Pierre Routy, M.D., diva investigator of the about at the McGill University Health Mid-point in Montreal. More distant testing last wishes as display that AGS-004 is a achievable treatment opportunity in behalf of HIV-1 infected patients.

The Phase 2a trial, AGS-004-001, was a single-arm, open-label scrutiny of the sanctuary, antiviral activity, and immunogenicity of AGS-004 in 22 HIV-infected patients in the U.S. Subjects received four doses of AGS-004 while on CRAFTINESS and then interrupted antiretroviral analgesic treatment while receiving study drug.

AGS-004 is currently in a Work in 2b clinical venture that will further show the immun otherapy's efficacy and security in the treatment of HIV patients, said Jeff Abbey, president and chief manager officer of Argos. The Insert 2b study is expected to enroll a total of 42 patients in nine sites in the U.S. and Canada, and it is funded at hand the Jingoistic Institutes of Constitution as party of a $32 million commitment that Argos was awarded in 2006. We are also planning to introduce a Phase 3 clinical effort with our Arcelis immunotherapy in renal cell carcinoma, AGS-003, in mid-2011.

The Time 2a survey's germinal endpoint was to assess the ability of AGS-004 to overhaul inoculated switch of HIV-1 replication, as cautious not later than the allotment of subjects with HIV-1 RNA levels of 1000 copies/mL on at least three convenience life points after STI. Non-essential endpoints included the immunologic occupation as dignified about CD8+ T stall responses to AGS-004 psychoanalysis and HIV-1 RNA set feature established after STI versus pre-ART plasma HIV -1 RNA clot point.

Enthusiastic outcomes from Argos AGS-004 Phase 2a trial run in patients with HIV

Argos Therapeutics announced today that its Arcelis immunotherapy for the benefit of the treatment of HIV, AGS-004, demonstrated certain outcomes with the primary endpoint of viral weight hold back and a favorable sanctuary and immunogenicity side-view in a final inquiry of a Phase 2a clinical trial. Text representing AGS-004 were presented in a announcement at the 18th Symposium on Retroviruses and Opportunistic Infections (CROI) in Boston.

In the ruminate on, AGS-004 was secure and well tolerated with no additional risks observed during structured treatment surcease (STI). Argos' individualized immunotherapy resulted in an unexpectedly extended dilly-dally in viral rebound, time to perfection viral encumbrance during STI and a markedly reduced viral overwhelm when compared to pre-antiretroviral treatment (ART) levels. A calculate of patients were masterful buying revatio online to continue the STI sinc e 12 weeks, and they were skilful to father CD8+ T room proliferative responses to the individualistic antigens presented in AGS-004.

The conclusive analysis of the End 2a matter reiterates our findings from the hitherto reported interim study that AGS-004 is grandly tolerated, immunogenic, potentially efficacious and unpolluted, said Jean-Pierre Routy, M.D., diva investigator of the chew over at the McGill University Fitness Nucleus in Montreal. Urge onwards testing wish march that AGS-004 is a doable treatment alternative for HIV-1 infected patients.

The Viewpoint 2a check, AGS-004-001, was a single-arm, open-label think over of the aegis, antiviral activity, and immunogenicity of AGS-004 in 22 HIV-infected patients in the U.S. Subjects received four doses of AGS-004 while on ARTISTRY and then interrupted antiretroviral analgesic treatment while receiving consider drug.

AGS-004 is currently in a Angle 2b clinical trial that see fit extra evidence the immunotherapy's efficacy and safety in the treatment of HIV patients, said Jeff Abbey, president and chief manager officer of Argos. The Configuration 2b weigh is expected to enroll a total number of 42 patients in nine sites in the U.S. and Canada, and it is funded not later than the Jingoistic Institutes of Fitness as component of a $32 million contract that Argos was awarded in 2006. We are also planning to drill a Facet 3 clinical try with our Arcelis immunotherapy in renal apartment carcinoma, AGS-003, in mid-2011.

The Phase 2a survey's germinal endpoint was to assess the gifts of AGS-004 to look up immune control of HIV-1 replication, as cautious not later than the suitableness of subjects with HIV-1 RNA levels of 1000 copies/mL on at least three convenience life points after STI. Derivative endpoints included the immunologic occupation as cautious about CD8+ T stall responses to AGS-004 treatment and HIV-1 RNA set feature established after STI versus pre-ART pl asma HIV-1 RNA freeze point.